Harvard Bioscience, Inc.
HBIO
$0.76
$0.011.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.69% | -6.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.69% | -6.08% | |||
| Cost of Revenue | -3.89% | -7.02% | |||
| Gross Profit | 4.23% | -5.34% | |||
| SG&A Expenses | -0.14% | -13.34% | |||
| Depreciation & Amortization | -26.42% | 0.17% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.43% | -9.95% | |||
| Operating Income | 139.58% | 61.88% | |||
| Income Before Tax | 49.69% | 95.56% | |||
| Income Tax Expenses | 246.43% | 106.17% | |||
| Earnings from Continuing Operations | 46.06% | 95.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.06% | 95.47% | |||
| EBIT | 139.58% | 61.88% | |||
| EBITDA | 57.37% | 3,116.13% | |||
| EPS Basic | 46.41% | 95.49% | |||
| Normalized Basic EPS | 47.59% | 25.64% | |||
| EPS Diluted | 41.75% | 95.49% | |||
| Normalized Diluted EPS | 47.59% | 25.64% | |||
| Average Basic Shares Outstanding | 0.57% | 0.47% | |||
| Average Diluted Shares Outstanding | 0.57% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||